GO:1990150 VEGF-A complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990150 (VEGF-A complex) is a homodimeric, extracellular protein complex containing two VEGF-A monomers that binds to and activates receptor tyrosine kinases.
• The complex is the principal ligand for VEGFR-1 (FLT1) and VEGFR-2 (KDR), and its structure has been resolved in complex with the full-length VEGFR-1 extracellular domain.
• VEGF-A complex signaling is central to angiogenesis, vascular permeability, and lymphangiogenesis, and is dysregulated in retinal diseases, diabetic kidney disease, and multiple cancers [1,5,6].
• Genetic determinants of VEGF-A levels are associated with telomere attrition, linking the complex to aging biology.
• FcγRIIb negatively regulates immune complex-induced VEGF-A production and intranodal lymphangiogenesis, revealing an immune-metabolic control node.
• The VEGF-A(165)/NRP-1 complex is a validated target for peptidomimetic inhibitors, illustrating druggability of the complex interface.
Description
The VEGF-A complex (GO:1990150) is a secreted, homodimeric protein assembly composed of two vascular endothelial growth factor A (VEGF-A) monomers that functions as the primary ligand for receptor tyrosine kinases on endothelial cells. It is the molecular entity through which VEGF-A exerts its canonical roles in angiogenesis, vascular permeability, and lymphangiogenesis, and it is a central node in both developmental and pathological vascular biology [1,5]. Because the complex is extracellular and its assembly is required for receptor activation, it represents a discrete target for therapeutic blockade and for functional interrogation by gene editing [2,8]. In human disease, the VEGF-A complex is implicated in retinal vascular disorders, diabetic kidney disease, and a broad spectrum of solid tumors [1,5,6]. Clinical evidence supports dual blockade of Ang-2 and VEGF-A in retinal diseases, underscoring the complex as a validated drug target. In ovarian cancer, modulation of the miR-200b-BMI-1/VEGF-A axis affects metastatic potential and cancer stemness, linking the complex to tumor progression. These observations make the VEGF-A complex a high-value subject for mechanistic and translational research. For researchers, GO:1990150 provides a precise annotation unit for cellular-component studies: it distinguishes the ligand complex from its receptors and from downstream signaling modules. Structural work on the full-length VEGFR-1 extracellular domain in complex with VEGF-A has clarified the stoichiometry and interface of the assembly, while genetic studies have associated VEGF-A levels with telomere attrition. Together, these findings position the VEGF-A complex as a tractable target for CRISPR-based models and for bioinformatics-driven discovery.
VEGF-A complex At A Glance
| GO ID | GO:1990150 |
|---|---|
| GO term | VEGF-A complex |
| Ontology | cellular_component |
| Synonym | vascular endothelial growth factor A complex |
| Definition | A homodimeric, extracellular protein complex containing two VEGF-A monomers. Binds to and activates a receptor tyrosine kinase. |
| Major function | Ligand complex that binds and activates receptor tyrosine kinases to drive angiogenesis, vascular permeability, and lymphangiogenesis [1,8] |
| Cellular location | Extracellular space / secreted |
| Subunit composition | Two VEGF-A monomers (homodimer) |
| Primary receptors | VEGFR-1 (FLT1) and VEGFR-2 (KDR) |
| Disease relevance | Retinal diseases, diabetic kidney disease, ovarian cancer, POEMS syndrome [1,4,5,6] |
What Is GO:1990150?
According to the QuickGO definition, GO:1990150 (VEGF-A complex) is a homodimeric, extracellular protein complex containing two VEGF-A monomers. It binds to and activates a receptor tyrosine kinase. In other words, the term describes the secreted VEGF-A homodimer as a functional ligand unit, not the VEGF-A polypeptide in isolation and not the receptor. The complex is the biologically active form that engages VEGFR-1 and VEGFR-2, and its assembly is a prerequisite for receptor activation and downstream signaling.
Why Is VEGF-A complex Important in Cell Biology?
The VEGF-A complex is important because it is the active, secreted ligand unit that initiates receptor tyrosine kinase signaling on endothelial cells, thereby controlling angiogenesis, vascular permeability, and lymphangiogenesis [1,8]. Its dysregulation contributes to retinal vascular disease, diabetic kidney disease, and cancer progression, and it is the direct target of clinically used VEGF-A blockade [1,5,6]. Because the complex is extracellular and structurally defined, it is also a favorable target for peptidomimetic inhibitors and for CRISPR-based functional studies [2,8].
• Drives angiogenesis and vascular permeability through VEGFR-1 and VEGFR-2 activation.
• Central to retinal vascular diseases and is targeted by dual Ang-2/VEGF-A blockade.
• Implicated in diabetic kidney disease as a mediator of glomerular injury.
• Promotes metastatic potential and cancer stemness in ovarian cancer via the miR-200b-BMI-1/VEGF-A axis.
• Regulated by FcγRIIb in immune complex-induced lymphangiogenesis.
• Associated with telomere attrition through genetic determinants of VEGF-A levels.
• Structurally resolved in complex with the full-length VEGFR-1 extracellular domain.
• Targetable by peptidomimetic inhibitors of the VEGF-A(165)/NRP-1 interface.
• Relevant to POEMS syndrome, a paraneoplastic disorder with VEGF-A involvement.
• Provides a discrete cellular-component annotation for ligand-complex studies.
Structure and Composition of VEGF-A complex
Homodimeric assembly of VEGF-A monomers
In simple terms: Two VEGF-A protein units join together to form the active signal.
The VEGF-A complex is a homodimer containing two VEGF-A monomers, as defined by GO:1990150 and supported by structural analysis of VEGF-A in complex with VEGFR-1. Dimerization creates the receptor-binding interface required for activation of receptor tyrosine kinases. The complex is extracellular, meaning it is secreted and acts on neighboring cells rather than within the producing cell.
Receptor engagement and stoichiometry
In simple terms: The dimer docks onto receptors on the cell surface and switches them on.
The full-length VEGFR-1 extracellular domain has been resolved in complex with VEGF-A, revealing the molecular details of ligand-receptor engagement. This structure clarifies how the homodimeric ligand presents epitopes for receptor binding and activation. The complex binds to and activates receptor tyrosine kinases, which is the defining functional property of GO:1990150.
Interaction with co-receptors such as NRP-1
In simple terms: The complex can also bind helper proteins that fine-tune signaling.
The VEGF-A(165) isoform forms a complex with neuropilin-1 (NRP-1), and peptidomimetic inhibitors of this interface have been generated by modifying the C-terminal arginine. This co-receptor interaction modulates the signaling output of the VEGF-A complex and represents a druggable surface. The existence of such co-receptor complexes expands the functional repertoire of the VEGF-A complex beyond the canonical receptor tyrosine kinases.
Extracellular localization and secretion
In simple terms: The complex is released outside the cell to act locally.
As an extracellular complex, VEGF-A is secreted and acts in the pericellular space to activate receptors on endothelial cells. This localization is a key annotation feature of GO:1990150 and distinguishes it from intracellular signaling complexes. Secretion and extracellular assembly are prerequisites for the complex to function as a ligand.
Key Genes Involved in GO:1990150 VEGF-A complex
The following genes and proteins are directly or functionally linked to the VEGF-A complex (GO:1990150) based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFA | Encodes the VEGF-A monomer that forms the homodimeric complex | Core subunit of GO:1990150; target for KO, knock-in, and overexpression studies |
| FLT1 (VEGFR-1) | Receptor tyrosine kinase that binds the VEGF-A complex | Structural studies of the full-length extracellular domain in complex with VEGF-A |
| KDR (VEGFR-2) | Receptor tyrosine kinase activated by the VEGF-A complex | Primary signaling receptor for angiogenesis; downstream of the complex |
| NRP1 | Co-receptor that binds VEGF-A(165) | Peptidomimetic inhibitor design against the VEGF-A(165)/NRP-1 complex |
| FCGR2B | FcγRIIb inhibits immune complex-induced VEGF-A production | Regulator of VEGF-A production and intranodal lymphangiogenesis |
| ANGPT2 (Ang-2) | Angiopoietin-2, co-targeted with VEGF-A in retinal disease | Dual blockade with faricimab in retinal diseases |
| MIR200B | microRNA regulating the BMI-1/VEGF-A axis | Modulates metastatic potential and cancer stemness in ovarian cancer |
| BMI1 | BMI-1, downstream effector of miR-200b | Part of the miR-200b-BMI-1/VEGF-A axis in ovarian cancer |
| HIF1A | Hypoxia-inducible factor 1-alpha, upstream regulator of VEGFA | Contextual regulator of VEGF-A expression in hypoxia |
| STAT3 | Transcription factor implicated in VEGF-A regulation | Downstream of immune complex signaling in lymphangiogenesis |
| NFKB1 | NF-kB subunit involved in inflammatory VEGF-A induction | Immune complex-induced VEGF-A production |
| VHL | Von Hippel-Lindau tumor suppressor regulating HIF and VEGF-A | Contextual regulator of VEGF-A levels |
| TGFB1 | TGF-beta 1, modulator of VEGF-A in kidney disease | Diabetic kidney disease biology |
| IL6 | Interleukin-6, inflammatory cytokine linked to VEGF-A | Inflammatory regulation of VEGF-A |
| TNF | Tumor necrosis factor, inducer of VEGF-A in inflammation | Immune complex-induced VEGF-A production |
| PIGF | Placental growth factor, VEGF family member | Comparative ligand for VEGFR-1 |
| VEGFB | VEGF family member sharing receptor interactions | Contextual comparison with VEGF-A complex |
| VEGFC | VEGF family member involved in lymphangiogenesis | Lymphangiogenesis context |
How Is VEGF-A complex Regulated?
The VEGF-A complex is regulated at multiple levels. FcγRIIb inhibits immune complex-induced VEGF-A production and intranodal lymphangiogenesis, establishing an inhibitory immune receptor checkpoint on VEGF-A output. Genetic determinants of VEGF-A levels have been associated with telomere attrition, indicating that inherited variation in VEGF-A regulation has systemic consequences. In diabetic kidney disease, VEGF-A is described as more than too much of a good thing, reflecting context-dependent regulation where both excess and insufficient VEGF-A signaling can be harmful. In ovarian cancer, the miR-200b-BMI-1/VEGF-A axis modulates VEGF-A expression and cancer stemness, providing a microRNA-level regulatory layer. Clinically, dual blockade of Ang-2 and VEGF-A with faricimab demonstrates that the pathway can be pharmacologically regulated in retinal diseases.
VEGF-A complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VEGFA | Retinal vascular disease; diabetic kidney disease; ovarian cancer | VEGFA knockout and knock-in endothelial cell models [1,5,6] |
| FLT1 | VEGF-A complex receptor binding; retinal disease | FLT1 point-mutation and knockout models |
| KDR | Angiogenesis signaling downstream of VEGF-A complex | KDR knockout and overexpression models |
| NRP1 | VEGF-A(165)/NRP-1 complex in cancer and vascular biology | NRP1 knockout and peptidomimetic inhibition models |
| FCGR2B | Immune complex-induced VEGF-A production and lymphangiogenesis | FcγRIIb knockout mouse and cell models |
Retinal vascular diseases
Emerging clinical evidence supports a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases, directly implicating the VEGF-A complex in retinal vascular pathology. The complex drives vascular permeability and neovascularization, which are hallmarks of these conditions. Targeting the complex or its pathway is therefore a validated therapeutic strategy.
Diabetic kidney disease
VEGF-A is implicated in diabetic kidney disease, where it is described as more than too much of a good thing, indicating that both excess and dysregulated VEGF-A signaling contribute to glomerular injury. The VEGF-A complex therefore represents a context-dependent therapeutic node in nephrology.
Ovarian cancer and tumor progression
Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b-BMI-1/VEGF-A axis in ovarian cancer, linking the VEGF-A complex to tumor progression. This axis provides a mechanistic route by which VEGF-A levels influence cancer stemness. The complex is thus relevant to solid tumor biology beyond angiogenesis.
POEMS syndrome and paraneoplastic vascular syndromes
POEMS syndrome is a paraneoplastic disorder in which VEGF-A is a key mediator, and the VEGF-A complex is therefore relevant to its pathophysiology. Elevated VEGF-A levels are characteristic of the syndrome and contribute to its vascular manifestations. This highlights the complex as a biomarker and potential therapeutic target in rare plasma cell disorders.
From VEGF-A complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is VEGFA required for VEGF-A complex formation and receptor activation? | VEGFA knockout cell model |
| Does a specific VEGFA point mutation alter receptor binding? | VEGFA point-mutation knock-in |
| Can a tagged VEGF-A be used to track complex secretion? | Tagged knock-in of VEGFA |
| Does overexpression of VEGFA increase angiogenic output? | VEGFA overexpression cell model |
| Which genes regulate VEGF-A complex levels? | CRISPR library screening |
| What is the transcriptional response to VEGF-A complex blockade? | RNA-seq after VEGFA knockout or inhibition |
How to Study the VEGF-A complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography / cryo-EM | Three-dimensional structure of the VEGF-A complex with receptors | Defining the ligand-receptor interface |
| Peptidomimetic inhibition assays | Disruption of VEGF-A(165)/NRP-1 complex | Inhibitor design and validation |
| CRISPR knockout | Requirement of a gene for complex formation or function | Functional genomics of VEGF-A complex |
| RNA-seq | Transcriptional changes after complex perturbation | Pathway analysis in cancer and vascular cells |
| Genetic association studies | Link between VEGF-A levels and telomere attrition | Aging and germline variation analysis |
| Clinical biomarker assays | VEGF-A levels in retinal disease and POEMS syndrome | Translational and diagnostic studies [1,4] |
| Immune complex stimulation assays | FcγRIIb-dependent VEGF-A production | Lymphangiogenesis and immune regulation |
| Diabetic kidney models | VEGF-A signaling in glomerular injury | Nephrology research |
Structural biology of the complex
The full-length VEGFR-1 extracellular domain has been resolved in complex with VEGF-A, providing atomic-level insight into the assembly. Such structural methods are essential for defining the interface that peptidomimetic inhibitors target. Structural data also inform the design of point mutations that disrupt or stabilize the complex.
Peptidomimetic and inhibitor studies
Peptidomimetic inhibitors of the VEGF-A(165)/NRP-1 complex have been obtained by modification of the C-terminal arginine, demonstrating that the complex interface is druggable. These studies provide a template for functional assays of complex inhibition. They also validate co-receptor engagement as a measurable output.
Genetic and expression analysis
Genetic determinants of VEGF-A levels have been associated with telomere attrition, showing that germline variation can be linked to complex abundance. Expression studies of the miR-200b-BMI-1/VEGF-A axis in ovarian cancer reveal how microRNAs tune VEGF-A output. Such analyses connect genotype to complex-level phenotypes [6,7].
Clinical and translational assays
Clinical evidence for dual Ang-2 and VEGF-A blockade with faricimab in retinal diseases provides a translational framework for measuring complex activity. VEGF-A levels are also relevant in POEMS syndrome, where they serve as a disease marker. These assays bridge mechanistic studies to patient outcomes [1,4].
How CRISPR Can Be Used to Study GO:1990150 VEGF-A complex
Knockout
CRISPR knockout of VEGFA eliminates the VEGF-A monomer and therefore prevents formation of the homodimeric VEGF-A complex, providing a clean loss-of-function model to test receptor activation and downstream angiogenesis. Knockout of receptors such as FLT1 or KDR can dissect which receptor mediates specific outputs of the complex. Knockout of FCGR2B can test the inhibitory role of FcγRIIb in immune complex-induced VEGF-A production.
Point Mutation
Point mutations in VEGFA can be introduced to disrupt the dimer interface or receptor-binding epitopes, allowing precise structure-function mapping of the VEGF-A complex. Such mutations can also mimic disease-associated variants that alter VEGF-A levels. Point mutations in NRP1 can probe the VEGF-A(165)/NRP-1 interface targeted by peptidomimetics.
Knock-in
Knock-in of epitope tags or fluorescent reporters into VEGFA enables tracking of VEGF-A complex secretion and localization in live cells. Knock-in of disease-relevant variants can model altered complex function in retinal or kidney disease [1,5]. Knock-in strategies can also be used to humanize the locus for drug testing.
Overexpression
Overexpression of VEGFA increases the abundance of the VEGF-A complex and can drive angiogenic and permeability phenotypes in vitro and in vivo [5,6]. Overexpression models are useful for testing whether increased complex levels are sufficient to promote cancer stemness or metastasis. They also provide a sensitized background for testing inhibitors of the complex.
How EDITGENE Supports VEGF-A complex Research
Researchers studying VEGF-A complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, receptor activation, or downstream vascular phenotypes. EDITGENE provides the full spectrum of CRISPR cell model services to move from correlation to causation with publication-ready reagents.
Contact EDITGENE today to design your custom CRISPR model for VEGF-A complex research.
Frequently Asked Questions About VEGF-A complex
What is the VEGF-A complex (GO:1990150)?
GO:1990150 is a homodimeric, extracellular protein complex containing two VEGF-A monomers that binds to and activates a receptor tyrosine kinase.
What genes are involved in the VEGF-A complex?
Key genes include VEGFA, which encodes the monomer, and the receptor genes FLT1 and KDR, as well as the co-receptor NRP1 [2,8].
Where is the VEGF-A complex located?
It is an extracellular, secreted complex that acts in the pericellular space to activate receptors on target cells.
What receptors does the VEGF-A complex activate?
It binds to and activates receptor tyrosine kinases, notably VEGFR-1 (FLT1) and VEGFR-2 (KDR).
How is the VEGF-A complex regulated?
It is regulated by FcγRIIb, genetic determinants of VEGF-A levels, the miR-200b-BMI-1 axis, and pharmacological blockade such as faricimab [1,3,6,7].
What diseases are linked to the VEGF-A complex?
Retinal vascular diseases, diabetic kidney disease, ovarian cancer, and POEMS syndrome are linked to the VEGF-A complex [1,4,5,6].
Can the VEGF-A complex be inhibited?
Yes, peptidomimetic inhibitors of the VEGF-A(165)/NRP-1 complex and dual Ang-2/VEGF-A blockade demonstrate that the complex is druggable [1,2].
What is the structure of the VEGF-A complex?
The full-length VEGFR-1 extracellular domain has been resolved in complex with VEGF-A, revealing the ligand-receptor interface.
How do I study the VEGF-A complex in the lab?
Common methods include CRISPR knockout, point mutation, knock-in tagging, overexpression, structural biology, and RNA-seq [2,6,8].
Is VEGF-A complex involved in aging?
Genetic determinants of VEGF-A levels have been associated with telomere attrition, linking the complex to aging biology.
Conclusion
The VEGF-A complex (GO:1990150) is a precisely defined extracellular homodimeric ligand assembly that activates receptor tyrosine kinases and governs angiogenesis, vascular permeability, and lymphangiogenesis. Its roles in retinal disease, diabetic kidney disease, ovarian cancer, and POEMS syndrome make it a high-priority target for mechanistic and translational research [1,4,5,6]. Structural and pharmacological studies have established the complex as a druggable entity, and CRISPR-based models now enable causal dissection of its assembly and function [2,8]. By combining knockout, point-mutation, knock-in, overexpression, and CRISPR screening approaches, researchers can move from association to causation for VEGF-A complex biology. EDITGENE provides the full suite of cell model and bioinformatics services to support such studies and to accelerate publication-ready discoveries.
References
- 1. Chaudhary V et al.. 2025. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases.. Graefes Arch Clin Exp Ophthalmol 263(5):1239-1247 PMID: 39708087
- 2. Tymecka D et al.. 2024. Peptidomimetic inhibitors of the VEGF-A(165)/NRP-1 complex obtained by modification of the C-terminal arginine.. Amino Acids 56(1):49 PMID: 39181965
- 3. Clatworthy MR et al.. 2014. FcγRIIb inhibits immune complex-induced VEGF-A production and intranodal lymphangiogenesis.. Proc Natl Acad Sci U S A 111(50):17971-6 PMID: 25475856
- 4. Dispenzieri A. 2007. POEMS syndrome.. Blood Rev 21(6):285-99 PMID: 17850941
- 5. Majumder S et al.. 2017. VEGF and the diabetic kidney: More than too much of a good thing.. J Diabetes Complications 31(1):273-279 PMID: 27836681
- 6. Cho JG et al.. 2025. Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b-BMI-1/VEGF-A axis in ovarian cancer.. Exp Mol Med 57(12):2782-2797 PMID: 41345229
- 7. Gorenjak V et al.. 2021. A genetic determinant of VEGF-A levels is associated with telomere attrition.. Aging (Albany NY) 13(20):23517-23526 PMID: 34661551
- 8. Markovic-Mueller S et al.. 2017. Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A.. Structure 25(2):341-352 PMID: 28111021
